(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Figure out How to Pick a Crematorium: Key Contemplations. - 2Instructions to Grasp the Innovation Behind 5G Pinnacles\
- 3Palestinians reel under winter rains as Israel blocks Gaza shelter supplies
- 45 Wellbeing Applications Assist You With remaining Fit
- 5How to watch the ‘Wicked: One Wonderful Night’ special — now streaming
- Vacation destinations in America
- Instructions to Investigate Different Open Record Extra Offers Actually
- Spots to Go Hang Floating
- Key takeaways from Sen. Bill Cassidy's interview on 'Face the Nation' with Margaret Brennan
- Tech Development Disclosed: A Survey of \Usefulness and Configuration in Concentration\ Tech Item
- 2024 Manual for Light Extravagance Room Feel: What's Moving
- Hamas Navy head, engineer of Khan Yunis tunnel network killed in Gaza, IDF confirms
- Passenger Missing After Going Overboard Disney Cruise Ship
- Putting resources into Yourself: Self-awareness Techniques
